Cardiomyopathy is a prevalent cardiovascular disease that affects individuals of all ages and can lead to life-threatening heart failure. Despite its variety in types, each with distinct characteristics and causes, our understanding of cardiomyopathy at a systematic biology level remains incomplete. Mass spectrometry-based techniques have emerged as powerful tools, providing a comprehensive view of the molecular landscape and aiding in the discovery of biomarkers and elucidation of mechanisms. This review highlights the significant potential of integrating proteomic and metabolomic approaches with specialized databases to identify biomarkers and therapeutic targets across different types of cardiomyopathies. In vivo and in vitro models, such as genetically modified mice, patient-derived or induced pluripotent stem cells, and organ chips, are invaluable in exploring the pathophysiological complexities of this disease. By integrating omics approaches with these sophisticated modeling systems, our comprehension of the molecular underpinnings of cardiomyopathy can be greatly enhanced, facilitating the development of diagnostic markers and therapeutic strategies. Among the promising therapeutic targets are those involved in extracellular matrix remodeling, sarcomere damage, and metabolic remodeling. These targets hold the potential to advance precision therapy in cardiomyopathy, offering hope for more effective treatments tailored to the specific molecular profiles of patients.

中文翻译：

---

用体内和体外模型和临床样本对心肌病进行综合蛋白质组学和代谢组学阐明


心肌病是一种普遍的心血管疾病，影响所有年龄段的人，并可能导致危及生命的心力衰竭。尽管心肌病的类型多种多样，每一种都有不同的特征和原因，但我们在系统生物学水平上对心肌病的理解仍然不完整。基于质谱的技术已成为强大的工具，提供了分子图谱的全面视图，并有助于发现生物标志物和阐明机制。本综述强调了将蛋白质组学和代谢组学方法与专业数据库相结合以识别不同类型心肌病的生物标志物和治疗靶点的巨大潜力。 体内和 体外模型，例如转基因小鼠、患者来源或诱导的多能干细胞以及器官芯片，对于探索这种疾病的病理生理复杂性非常宝贵。通过将组学方法与这些复杂的建模系统相结合，我们可以大大增强我们对心肌病分子基础的理解，从而促进诊断标志物和治疗策略的开发。有前途的治疗靶点包括参与细胞外基质重塑、肌节损伤和代谢重塑的靶点。这些靶点具有推进心肌病精准治疗的潜力，为针对患者特定分子特征量身定制的更有效治疗带来希望。